These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 31517533)

  • 1. Recent tau-targeted clinical strategies for the treatment of Alzheimer's disease.
    Lee HE; Lim D; Lee JY; Lim SM; Pae AN
    Future Med Chem; 2019 Aug; 11(15):1845-1848. PubMed ID: 31517533
    [No Abstract]   [Full Text] [Related]  

  • 2. Tau Biology and Tau-Directed Therapies for Alzheimer's Disease.
    Bakota L; Brandt R
    Drugs; 2016 Mar; 76(3):301-13. PubMed ID: 26729186
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tau-Targeted Multifunctional Nanocomposite for Combinational Therapy of Alzheimer's Disease.
    Chen Q; Du Y; Zhang K; Liang Z; Li J; Yu H; Ren R; Feng J; Jin Z; Li F; Sun J; Zhou M; He Q; Sun X; Zhang H; Tian M; Ling D
    ACS Nano; 2018 Feb; 12(2):1321-1338. PubMed ID: 29364648
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tau-based therapeutics for Alzheimer's disease: active and passive immunotherapy.
    Panza F; Solfrizzi V; Seripa D; Imbimbo BP; Lozupone M; Santamato A; Tortelli R; Galizia I; Prete C; Daniele A; Pilotto A; Greco A; Logroscino G
    Immunotherapy; 2016 Sep; 8(9):1119-34. PubMed ID: 27485083
    [TBL] [Abstract][Full Text] [Related]  

  • 5. No "breakthrough" in Alzheimer's disease.
    Wise J
    BMJ; 2016 Aug; 354():i4474. PubMed ID: 27531826
    [No Abstract]   [Full Text] [Related]  

  • 6. "Lest we forget you--methylene blue...".
    Schirmer RH; Adler H; Pickhardt M; Mandelkow E
    Neurobiol Aging; 2011 Dec; 32(12):2325.e7-16. PubMed ID: 21316815
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tau aggregation inhibitor therapy: an exploratory phase 2 study in mild or moderate Alzheimer's disease.
    Wischik CM; Staff RT; Wischik DJ; Bentham P; Murray AD; Storey JM; Kook KA; Harrington CR
    J Alzheimers Dis; 2015; 44(2):705-20. PubMed ID: 25550228
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tau-directed approaches for the treatment of Alzheimer's disease: focus on leuco-methylthioninium.
    Seripa D; Solfrizzi V; Imbimbo BP; Daniele A; Santamato A; Lozupone M; Zuliani G; Greco A; Logroscino G; Panza F
    Expert Rev Neurother; 2016; 16(3):259-77. PubMed ID: 26822031
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development of tau aggregation inhibitors for Alzheimer's disease.
    Bulic B; Pickhardt M; Schmidt B; Mandelkow EM; Waldmann H; Mandelkow E
    Angew Chem Int Ed Engl; 2009; 48(10):1740-52. PubMed ID: 19189357
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tau-Centric Targets and Drugs in Clinical Development for the Treatment of Alzheimer's Disease.
    Panza F; Solfrizzi V; Seripa D; Imbimbo BP; Lozupone M; Santamato A; Zecca C; Barulli MR; Bellomo A; Pilotto A; Daniele A; Greco A; Logroscino G
    Biomed Res Int; 2016; 2016():3245935. PubMed ID: 27429978
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Alzheimer's Disease Drug Discovery--11th International Conference--Targeting Pathological Tau. 27-28 September 2010, Jersey City, NJ, USA.
    Wolfe MS
    IDrugs; 2010 Dec; 13(12):828-9. PubMed ID: 21154135
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development of a Tau-Targeted Drug Delivery System Using a Multifunctional Nanoscale Metal-Organic Framework for Alzheimer's Disease Therapy.
    Zhao J; Yin F; Ji L; Wang C; Shi C; Liu X; Yang H; Wang X; Kong L
    ACS Appl Mater Interfaces; 2020 Oct; 12(40):44447-44458. PubMed ID: 32897042
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An evaluation of hydromethylthionine as a treatment option for Alzheimer's disease.
    Hashweh NN; Bartochowski Z; Khoury R; Grossberg GT
    Expert Opin Pharmacother; 2020 Apr; 21(6):619-627. PubMed ID: 32037892
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Assays for the Screening and Characterization of Tau Aggregation Inhibitors.
    Rickard JE; Horsley D; Wischik CM; Harrington CR
    Methods Mol Biol; 2017; 1523():129-140. PubMed ID: 27975248
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Microtubule affinity-regulating kinases are potential druggable targets for Alzheimer's disease.
    Annadurai N; Agrawal K; Džubák P; Hajdúch M; Das V
    Cell Mol Life Sci; 2017 Nov; 74(22):4159-4169. PubMed ID: 28634681
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mechanistic basis of phenothiazine-driven inhibition of Tau aggregation.
    Akoury E; Pickhardt M; Gajda M; Biernat J; Mandelkow E; Zweckstetter M
    Angew Chem Int Ed Engl; 2013 Mar; 52(12):3511-5. PubMed ID: 23401175
    [No Abstract]   [Full Text] [Related]  

  • 17. Tau protein aggregation in Alzheimer's disease: An attractive target for the development of novel therapeutic agents.
    Jouanne M; Rault S; Voisin-Chiret AS
    Eur J Med Chem; 2017 Oct; 139():153-167. PubMed ID: 28800454
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Structure and mechanism of action of tau aggregation inhibitors.
    Cisek K; Cooper GL; Huseby CJ; Kuret J
    Curr Alzheimer Res; 2014; 11(10):918-27. PubMed ID: 25387336
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lithium: a novel treatment for Alzheimer's disease?
    Zhong J; Lee WH
    Expert Opin Drug Saf; 2007 Jul; 6(4):375-83. PubMed ID: 17688381
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dementia Therapy Targeting Tau.
    Buee L
    Adv Exp Med Biol; 2019; 1184():407-416. PubMed ID: 32096053
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.